Enrolment in this trial is expected to continue through the first quarter of 2025. Satellos is on track to submit a Phase II ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

The former COO of franchisee DMD Ventures accused the company’s co-founders of using corporate funds to pay for lavish ...

The former chief operating officer of several high-volume Twin Peaks restaurants is suing his business partners, alleging ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic a ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

Pharmaceuticals announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel ...

Dr. Mitzi Morris, a distinguished dentist in Roswell, GA, has been honored as a 2025 Top Patient Rated Dentist by Find Local ...